HN2011001247A - Inhibidores de cinana akt y p70 s6 - Google Patents

Inhibidores de cinana akt y p70 s6

Info

Publication number
HN2011001247A
HN2011001247A HN2011001247A HN2011001247A HN2011001247A HN 2011001247 A HN2011001247 A HN 2011001247A HN 2011001247 A HN2011001247 A HN 2011001247A HN 2011001247 A HN2011001247 A HN 2011001247A HN 2011001247 A HN2011001247 A HN 2011001247A
Authority
HN
Honduras
Prior art keywords
inhibitors
cinana
akt
formula
compounds
Prior art date
Application number
HN2011001247A
Other languages
English (en)
Inventor
Dean Dally Robert
Joseph Sajan
Alan Shepherd Timothy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HN2011001247A publication Critical patent/HN2011001247A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A INHIBIDORES DE CINASA P70 S6 TAMBIEN PROPORCIONA COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN COMPUESTOS DE FORMULA I, USOS DE COMPUESTOS DE FORMULA I Y METODOS PARA USAR COMPUESTOS DE FORMULA I.
HN2011001247A 2008-11-11 2011-05-03 Inhibidores de cinana akt y p70 s6 HN2011001247A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11

Publications (1)

Publication Number Publication Date
HN2011001247A true HN2011001247A (es) 2013-05-20

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011001247A HN2011001247A (es) 2008-11-11 2011-05-03 Inhibidores de cinana akt y p70 s6

Country Status (37)

Country Link
US (1) US8148387B2 (es)
EP (1) EP2358710B1 (es)
JP (1) JP5432275B2 (es)
KR (1) KR101334460B1 (es)
CN (1) CN102216302B (es)
AR (1) AR074072A1 (es)
AU (1) AU2009314324B2 (es)
BR (1) BRPI0921916A2 (es)
CA (1) CA2743019C (es)
CO (1) CO6382114A2 (es)
CR (1) CR20110240A (es)
CY (1) CY1113409T1 (es)
DK (1) DK2358710T3 (es)
DO (1) DOP2011000129A (es)
EA (1) EA018947B1 (es)
EC (1) ECSP11011048A (es)
ES (1) ES2391704T3 (es)
HK (1) HK1158203A1 (es)
HN (1) HN2011001247A (es)
HR (1) HRP20120738T1 (es)
IL (1) IL211940A (es)
JO (1) JO2822B1 (es)
MA (1) MA32776B1 (es)
MX (1) MX2011005000A (es)
MY (1) MY161461A (es)
NZ (1) NZ592062A (es)
PA (1) PA8846901A1 (es)
PE (1) PE20110807A1 (es)
PL (1) PL2358710T3 (es)
PT (1) PT2358710E (es)
RS (1) RS52520B (es)
SI (1) SI2358710T1 (es)
TN (1) TN2011000207A1 (es)
TW (1) TWI422587B (es)
UA (1) UA100190C2 (es)
WO (1) WO2010056563A1 (es)
ZA (1) ZA201102549B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102548970B (zh) 2009-07-02 2015-11-25 赛诺菲 新型(6-氧代-1,6-二氢嘧啶-2-基)酰胺衍生物、其制备方法以及其作为akt(pkb)磷酸化抑制剂的医药用途
AU2010310786B2 (en) * 2009-10-23 2014-03-27 Eli Lilly And Company AKT inhibitors
EA024890B1 (ru) 2011-04-07 2016-10-31 Байер Интеллектчуал Проперти Гмбх Имидазопиридазины в качестве ингибиторов akt киназы
ES2547687T3 (es) * 2011-07-09 2015-10-08 Xuanzhu Pharma Co., Ltd. Forma cristalina I de sal de un inhibidor de dipeptidil-peptidasa IV y procedimiento de preparación y uso de la misma
EP2755965B1 (en) * 2011-09-12 2017-07-26 Merck Patent GmbH Novel imidazole amines as modulators of kinase activity
WO2013040044A1 (en) 2011-09-12 2013-03-21 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
EP2920178B1 (en) 2012-11-16 2016-12-21 Merck Patent GmbH Novel heterocyclic derivatives as modulators of kinase activity (p70s6 and akt)
ES2807539T3 (es) * 2012-11-16 2021-02-23 Merck Patent Gmbh Derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa
AR095202A1 (es) * 2013-03-11 2015-09-30 Merck Patent Gmbh Heterociclos como moduladores de la actividad quinasa
EP3105224A1 (en) * 2014-02-11 2016-12-21 Merck Patent GmbH Pyrimidine imidazole amines as modulators of kinase activity
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Ｃｇｒｐ受體拮抗劑
ES2882018T3 (es) 2016-05-20 2021-11-30 Taiho Pharmaceutical Co Ltd Nuevo derivado de 5H-pirrolo[2,3-d]pirimidin-6(7H)-ona
BR112022017856A2 (pt) * 2020-03-17 2022-11-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado bicíclico fundido, método de preparação do mesmo e uso farmacêutico do mesmo
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
TW202328138A (zh) 2021-09-17 2023-07-16 大陸商江蘇恒瑞醫藥股份有限公司 稠合二環類衍生物的可藥用鹽、晶型及其製備方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076338B2 (en) 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2006071819A1 (en) 2004-12-28 2006-07-06 Exelixis, Inc. [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
WO2007003960A1 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
US20090082370A1 (en) 2006-04-25 2009-03-26 Neil Thomas Thompson Pharmaceutical Combinations of PK Inhibitors and Other Active Agents
US8796293B2 (en) 2006-04-25 2014-08-05 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
HK1158203A1 (en) 2012-07-13
UA100190C2 (en) 2012-11-26
EP2358710B1 (en) 2012-08-15
CO6382114A2 (es) 2012-02-15
MX2011005000A (es) 2011-05-25
ES2391704T3 (es) 2012-11-29
CY1113409T1 (el) 2016-06-22
IL211940A (en) 2014-01-30
JP2012508274A (ja) 2012-04-05
ECSP11011048A (es) 2011-06-30
PE20110807A1 (es) 2011-10-31
US8148387B2 (en) 2012-04-03
NZ592062A (en) 2013-03-28
JO2822B1 (en) 2014-09-15
CN102216302B (zh) 2013-08-21
AR074072A1 (es) 2010-12-22
RS52520B (en) 2013-04-30
KR20110074578A (ko) 2011-06-30
MA32776B1 (fr) 2011-11-01
CA2743019C (en) 2013-08-13
EP2358710A1 (en) 2011-08-24
EA018947B1 (ru) 2013-11-29
EA201170680A1 (ru) 2011-12-30
CR20110240A (es) 2011-06-09
MY161461A (en) 2017-04-14
DOP2011000129A (es) 2016-02-29
US20100120801A1 (en) 2010-05-13
TWI422587B (zh) 2014-01-11
PL2358710T3 (pl) 2012-12-31
TN2011000207A1 (en) 2012-12-17
CN102216302A (zh) 2011-10-12
PT2358710E (pt) 2012-10-01
CA2743019A1 (en) 2010-05-20
JP5432275B2 (ja) 2014-03-05
AU2009314324B2 (en) 2013-06-20
DK2358710T3 (da) 2012-09-03
ZA201102549B (en) 2012-09-26
SI2358710T1 (sl) 2012-11-30
IL211940A0 (en) 2011-06-30
KR101334460B1 (ko) 2013-12-02
WO2010056563A1 (en) 2010-05-20
TW201022268A (en) 2010-06-16
HRP20120738T1 (hr) 2012-10-31
AU2009314324A1 (en) 2010-05-20
BRPI0921916A2 (pt) 2015-12-29
PA8846901A1 (es) 2010-06-28

Similar Documents

Publication Publication Date Title
HN2011001247A (es) Inhibidores de cinana akt y p70 s6
ECSP099721A (es) Inhibidores de cinasa p70 s6
CR10782A (es) Compuestos para inhibir la progresion mitotica
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
CU23774A3 (es) Inhibición de arni de expresión de alfa-enac
BR112012011328A2 (pt) inibidores de akt
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
UY33735A (es) Compuestos antivirales
BR112013007362A2 (pt) composição farmacêutica
GT200900027A (es) Compuestos organicos
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
PA8827101A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
HN2008001723A (es) Nitrilos espirociclicos como inhibidores de proteasa
CL2012003104A1 (es) Compuestos derivados de multiheteroarilos, inhibidores de prostaglandina d sintasa hematopoyetica (h-pgds); y composicion farmaceutica que los comprende.
GT200600117A (es) Nuevos compuestos farmaceuticos
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
SV2010003650A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CO6321288A2 (es) Sales de compuestos inhibidores de vih
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CR11601A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
UY31128A1 (es) Formulacion de nevirapina de liberacion prolongada
ECSP11011486A (es) Producción de hidrocarburos de isopreno mejorada que usa citanobacterias diseñadas geneticamente